2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow Anal Margin Squamous Cell Carcinoma: new trials by email Literature Review of Anal Margin Squamous Cell Carcinoma trials Research Report on Anal Margin Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-11-12 |
| Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study Biopsy, Biospecimen Collection, Capecitabine - Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 252 | 2020-01-02 | 2026-10-19 |
Anus Neoplasms (2) · Anal Canal Carcinoma (1) · HIV Infections (1) · Rectal Neoplasms (1)
Anus Diseases (2) · Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1)
Capecitabine (2) · Fluorodeoxyglucose F18 (2) · Fluorouracil (2) · Magnetic Resonance Spectroscopy (2) · Mitomycin (2) · Mitozytrex (2) · Radiotherapy, Intensity-Modulated (2) · Specimen Handling (2) · dehydroftorafur (2) · Biopsy (1) · Colonoscopy (1) · Nivolumab (1) · Proctoscopy (1) · Sentinel Lymph Node Biopsy (1) · Sigmoidoscopy (1)
ECOG-ACRIN Cancer Research Group (1) · National Cancer Institute (NCI) (1)
United States (2)
Jennifer A Dorth (1) · Rafi Kabarriti (1)
U10CA180820 (1), UM1CA121947 (1)